Abstract: The tricyclic heterocycles disclosed herein are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases, in particular cancer.

Abstract: A head stabilization device useable for stabilizing a head of a patient during a medical procedure includes a modular design where stabilization assemblies of various configurations are interchangeable at receiving portions along a frame. The device includes a tensioning feature positioned away from the stabilization assembly but still operable to increase or decrease an amount of force the stabilization assembly applies to the patient's head. The device includes a locking feature for a stabilization assembly having a rotatable member having one or more stabilization features connected thereto. The device includes an adjustment feature to adjust a spacing between frame members with the adjustment feature providing a continuous range of adjustment rather than finite adjustment increments.

Abstract: Tricyclic heterocycles are disclosed. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases, in particular cancer.

Abstract: Compounds of the formula I are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer. R1 denotes H, Hal, CF3, NO2, A, [C(R3)2]nN(R3)2, [C(R3)2]nHet1, OR3, O[C(R3)2]nN(R3)2, O[C(R3)2]nS(O)mR3, O[C(R3)2]nCOOR3, O[C(R3)2]nCOON(R3)2, O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1, O[C(R3)2]nPh, or O[C(R3)2]nCyc. R2 denotes H or CH3. R3 denotes H or A. V denotes H or Hal. X denotes O or N(R3). Y denotes phenylene, pyridin-diyl, thiophen-diyl, 1,3-thiazol-diyl or pyrazol-diyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal and/or A. Z denotes CON(R3)2, phenyl, Het4 or —O-A.

Abstract: Compounds of the formula I are provided. These compounds can inhibit c-Kit kinase and can be employed for the treatment of cancer.

Abstract: A joint assembly and adapter couple with a head stabilization device about one or more circumferential toothed rings of the head stabilization device. This coupling provides rotatable adjustment of the head stabilization device about two degrees of freedom including a first longitudinal axis of the head stabilization device and a second longitudinal axis of the joint assembly. The toothed rings of the head stabilization device can have multiple coupling locations to allow for a third degree of freedom for adjustment along the first longitudinal axis. A locking feature is coupled with the adapter to actuate the adapter and joint assembly for selective adjustment of the head stabilization device among the various degrees of freedom for adjustment.

Abstract: The invention relates to new pyridinyl sulfonamide derivatives of the formula wherein R1, A and n are as defined herein, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: The invention relates to new pyridinyl sulfonamide derivatives of the formula wherein R1, A and n are as defined herein, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: A head stabilization device useable for stabilizing a head of a patient during a medical procedure includes a modular design where stabilization assemblies of various configurations are interchangeable at receiving portions along a frame. The device includes a tensioning feature positioned away from the stabilization assembly but still operable to increase or decrease an amount of force the stabilization assembly applies to the patient's head. The device includes a locking feature for a stabilization assembly having a rotatable member having one or more stabilization features connected thereto. The device includes an adjustment feature to adjust a spacing between frame members with the adjustment feature providing a continuous range of adjustment rather than finite adjustment increments.

Abstract: The invention relates to new heteroaryl derivatives of the formula wherein X is selected from the group consisting of: N and CH; X is selected from the group consisting of: N and CF; (with the proviso that at least one of X1 and X2 is N), and A is as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: The invention relates to new benzonitrile derivatives of the formula (I) wherein R1 to R3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: The invention relates to new heteroaryl derivatives of the formula wherein X is selected from the group consisting of: N and CH; X is selected from the group consisting of: N and CF; (whith the proviso that at least one of X1 and X2 is N), and A is as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: The invention relates to new benzonitrile derivatives of the formula (I) wherein R1 to R3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: The application relates to novel sulfoximine substituted quinazoline derivatives of formula wherein Ar, R1, R2 and R3 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

Abstract: The invention relates to new pyridinyl derivatives of the formula wherein R1 and A are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: The invention relates to new pyridinyl derivatives of the formula wherein R1 and A are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: The application relates to novel sulfoximine substituted quinazoline derivatives of formula (I) wherein Ar, R1, R2 and R3 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.